Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Martí Carvajal, Arturo J ^a   Cardona, Andrés Felipe ^b   Lawrence, Able ^c  

^a Iberoamerican Cochrane Network   (Venezuela)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ATYPICAL MYCOBACTERIOSIS; AUTONOMIC NEUROPATHY; BACTEREMIA; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MUCOSA ILAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PNEUMONIA; RECURRENT DISEASE; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 70049111768     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005419.pub2     Document Type: Review

References (117)

1. * Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al.Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543 [MEDLINE: 15914552]
2. Kaplan LD, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Proceedings of the American Society of Clinical Oncology. 2003; Vol.22:564.
3. Kaplan L, Kahn J, Crowe S, Volberding P, Grossberg H, McManus N, Mills J, International Conference on AIDS. A randomized trial of chemotherapy with or without recombinant granulocyte monocyte colony stimulating factor (rGMCSF) in HIV-associated non-Hodgkin's lymphoma (NHL): effect of treatment on serum HIV p24 antigen levels. International Conference on AIDS. 1990; Vol.6 (Suppl 3):213 ( Abstract S.B.510).
4. * Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, et al.Clinical and virologic effects of recombinant human granulocyte- macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Journal of Clinical Oncology 1991;9:929-940 [MEDLINE: 2033429]
5. * Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al.Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. New England Journal of Medicine 1997;336:1641-1648 [MEDLINE: 9171066]
6. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. Journal of Clinical Oncology 1998;16:3601-3606 [MEDLINE: 9817281] (Pubitemid 28506774)
7. Mounier N, Spina M, Gabarre J, Raphael M, Carbone A, Vaccher E, et al.HIV-related Non-Hodgkin's Lymphomas before and after Haart: final analysis on 485 patients treated with risk-adapted intensive chemotherapy from the French-Italian Cooperative Group (GELAGICAT). Haematologica. 2005; Vol.90 Suppl 2:324.
8. * Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, et al.AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006;107:3832-3840 [MEDLINE: 16410446]
9. Tirelli U, Spina M, Errante D, Vaccher E, Tavio M, Nasti G, et al.Therapy of HIV-related non-Hodgkins lymphoma: An european multicentric randomized stduy in patients (PTS) stratified according to their prognostic factors: Preliminary results. Tumori. 1997; Vol.83 Suppl 1:4.
10. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al.Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491 [MEDLINE: 11504980] (Pubitemid 32744595)
11. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al.Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Journal of Clinical Oncology 2006;24:4123-4128 [MEDLINE: 16896005] (Pubitemid 46622288)
12. Feigal EG, Petroni GR, Freter C, Johnson JL, Barcos M, Peterson BA. Pilot trial of cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide + antiretrovirals + G-CSF + erythropoietin in AIDS-associated non-Hodgkin's lymphoma: CALGB 9155. ASCO Annual Meeting. 1997; Vol.Abstract: 195.
13. Gabarre J, Lepage E, Thyss A, Tubiana R, Bastion Y, Schlaifer D, et al.Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Annals of Oncology 1995;6:1025-1032 [MEDLINE: 8750156] (Pubitemid 26015250)
14. Gisselbrecht C, Oksenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP, et al.Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. American Journal of Medicine 1993;95:88-96. [MEDLINE: 7689296]
15. Hoffmann C, Wolf E, Faetkenheuer G, Wyen C, Stellbrink HJ, van Lunzen J, et al.The Short and Intensive B-ALL Protocol Is a Highly Effective Regimen in Patients with AIDS-associated Burkitt or Burkitt-like Lymphoma. Conference on Retroviruses and Opportunistic Infections (11th : 2004 : San Francisco, Calif, USA). 2004: abstract 787.
16. Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, et al.Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. Journal of the American Medical Association 1991;266:84-88 [MEDLINE: 1710673]
17. Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, et al.Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. Journal of Clinical Oncology 2004;22:2662-2670 [MEDLINE: 15226333] (Pubitemid 41103754)
18. Newell M, Goldstein D, Milliken S, Lewis C, Hoy J, Thomson B, et al.Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma. Annals of Oncology 1996;7:1029-1036 [MEDLINE: 9037361] (Pubitemid 27050826)
19. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, et al.Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. British Journal of Haematology 2008;140:411-419 [MEDLINE: 18162120]
20. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, et al.Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. Journal Clinical Oncology 1996;14:3026-3035 [MEDLINE: 8918501] (Pubitemid 26371462)
21. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al.Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). Journal Clinical Oncology 2004;22:1491-1500 [MEDLINE: 15084622] (Pubitemid 41103632)
22. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al.Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-1897 [MEDLINE: 15550484] (Pubitemid 40731769)
23. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. Journal of Clinical Oncology 1998;16:3601-3606 [MEDLINE: 9817281] (Pubitemid 28506774)
24. Tirelli U, Errante D, Oksenhendler E, Spina M, Vaccher E, Serraino D, et al.Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Annals of Oncology 1992;3:843-847 [MEDLINE: 1286047] (Pubitemid 23002478)
25. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, et al.Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Research 2002;159:149-153 [MEDLINE: 11785839]
26. Vaccher E, Spina M, diGennaro G, Talamini R, Nasti G, Schioppa O, et al.Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-163 [MEDLINE: 11148572] (Pubitemid 32052626)
27. Walsh C, Wernz JC, Levine A, Rarick M, Willson E, Melendez D, et al.Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. Journal of Acquired Immune Deficiency Syndromes 1993;6:265-271 [MEDLINE: 7680712] (Pubitemid 23099729)
28. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, et al.Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer 2006;106:1560-1568 [MEDLINE: 16502436]
29. McLaughlin PW (Study chair). Pilot study in AIDS-related lymphomas. http://www.clinicaltrials.gov. Accessed Feb 21, 2009. [: NCT00002524]
30. Wilson WH (Prinicpal investigator). Short-course EPOCH-rituximab for untreated CD-20+ HIV-associated lymphomas. http://www.clinicaltrials.gov. February 17, 2009. [: NCT00020384]
31. Kaplan L (Investigator). A randomized phase II trial of EPOCH given either concurrently or sequentially with rituximab In patients with intermediate or high-grade HIV-associated B-cell non-Hodgkin's lymphoma. http://www.clinicaltrials.gov. Accessed Jan 18, 2009. [: NCT00049036]
32. Altman DG. Statistics and ethics in medical research: III. How large a sample?. Brithish Medical Journal 1980;281:1336-1338 [MEDLINE: 7437789]
33. Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. Journal of Clinical Oncology 2007;25:3482-3487 [MEDLINE: 17687153] (Pubitemid 47310887)
34. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337(8745):805-809.
35. Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003;22:6646-6659
36. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al.Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344 [MEDLINE: 11588028]
37. Bhaskaran K, Brettle R, Porter K, Walker AS, CASCADE Collaboration. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS 2004;18:673-681 [MEDLINE: 15090773] (Pubitemid 38393467)
38. Biggar RJ, Rosenberg PS, Coté T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. International Journal of Cancer 1996;68:754-758 [MEDLINE: 8980179]
39. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematology/Oncology Clinics of North America 1996;10:997-1010. [MEDLINE: 8880192]
40. Booth CM, Tannock I. Reflections on medical oncology: 25 years of clinical trials - where have we come and where are we going?. Journal of Clinical Oncology 2008;26:6-8. [MEDLINE: 18165630]
41. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. British Journal of Haematology 2005;130:662-700. [MEDLINE: 16115121]
42. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. The Oncologist 2005;10:412-426 [MEDLINE: 15967835] (Pubitemid 40993569)
43. Clarke CA, Glaser SL. Epidemiologic trends in HIV-associated lymphomas. Current Opinion in Oncology 2001;13:354-359 [MEDLINE: 11555712]
44. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al.Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. Journal of the National Cancer Institute 2005;97:425-432 [MEDLINE: 15770006] (Pubitemid 40528605)
45. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002;346:235-242 [MEDLINE: 11807147] (Pubitemid 34438862)
46. Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematology/oncology clinics of North America 2003;17:889-899 [MEDLINE: 12852661]
47. Coté TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al.Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. International Journal of Cancer 1997;73:645-650 [MEDLINE: 9398040] (Pubitemid 127483058)
48. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncology 2003;4:110-119 [MEDLINE: 12573353] (Pubitemid 36193171)
49. Edwards SJ, Lilford RJ, Braunholtz D, Jackson J. Why " underpowered" trials are not necessarily unethical. Lancet 1997;350:804-807 [MEDLINE: 9298015] (Pubitemid 27387219)
50. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al.Cancer risk in people infected with human immunodeficiency virus in the United States. Internationsl Journal of Cancer 2008;123:187-194 [MEDLINE: 18435450] (Pubitemid 351705208)
51. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial: A survey of 71 "negative" trials. New England Journal of Medicine 1978;299:690-694 [MEDLINE: 355881]
52. Gastaldi R, Martino P, Gentile G, Cafolla A, Cordone I, Giannini G, et al.High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study. Haematologica 2001;86:1051-1059 [MEDLINE: 11602411] (Pubitemid 33031871)
53. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Seminars in Oncology 2000;27:390-401. [MEDLINE: 10950365]
54. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. Journal of Clinical Pathology 2007;60:1365-1372 [MEDLINE: 18042692]
55. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155-1161 [MEDLINE: 12004274] (Pubitemid 34533854)
56. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005;37:409-419 [MEDLINE: 16373224]
57. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67. [MEDLINE: 17617273]
58. Hebert RS, Wright SM, Dittus RS, Elasy TA. Prominent medical journals often provide insufficient information to assess the validity of studies with negative results. Journal of Negative Results in Biomedicine 2002;1:1. [MEDLINE: 12437785]
59. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org 2008.
60. Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al.Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521-1529 [MEDLINE: 12824790] (Pubitemid 36900553)
61. Holmgren E. Are phase 2 screening trials in oncology obsolete?. Statistics in Medicine 2008;27:556-567 [MEDLINE: 17661436] (Pubitemid 351266342)
62. European Federation of Pharmaceutical Industries Associations - EFPIA. International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/cache/compo/ 276-254-1.html. Accessed on February 24, 2009.
63. Jacomet C, Lesens O, Villemagne B, Darcha C, Tournilhac O, Henquell C, et al.Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003 [Lymphomes non hodgkiniens et hodgkiniens et infection VIH : fréquence, pronostic et reconstitution immune sous trithérapie antiré trovirale ; CHU de Clermont-Ferrand, 1991-2003]. Médecine et Maladies Infectieuses 2006;36:157-162 [MEDLINE: 16503104]
64. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, et al.AIDS-associated non-Hodgkins lymphoma in San Francisco. JAMA 1989;261:719-724 [MEDLINE: 2536124] (Pubitemid 19047318)
65. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al.Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. New England Journal of Medicine 1997;336:1641-1648 [MEDLINE: 9171066]
66. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al.Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412 [MEDLINE: 11719381]
67. Koo S, Baden LR. Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy. Journal of the National Comprehensive Cancer Network 2008;6:2002-2013 [MEDLINE: 18319052] (Pubitemid 351340527)
68. Launay O, Guillevin L. Epidemiology of HIV-associated malignancies [Épidémiologie des tumeurs malignes associées á l'infection par le VIH]. Bulletin du Cancer 2003;90:387-392 [MEDLINE: 12850760]
69. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Seminars in Oncology 2000;27:442-453 [MEDLINE: 10950371]
70. Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer 2002;94:1500-1506 [MEDLINE: 11920507] (Pubitemid 34212644)
71. Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, et al.Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. Journal of Clinical Oncology 2004;22:2662-2670 [MEDLINE: 15226333] (Pubitemid 41103754)
72. Levine AM. AIDS-related lymphoma. Seminars in Oncology Nursing 2006;22:80-89 [MEDLINE: 16720230]
73. Levine AM. Management of AIDS-related lymphoma. Current Opinion in Oncology 2008;20:522-528 [MEDLINE: 19106654]
74. Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA : a Cancer Journal for Clinicians 2005;55:229-41; 260-1, 264. [MEDLINE: 16020424]
75. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. Journal of Clinical Oncology 2005;23:4430-4438 [MEDLINE: 15883411] (Pubitemid 46207018)
76. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Current Opinion in Oncology 2000;12:438-444 [MEDLINE: 10975551] (Pubitemid 32268880)
77. Little RF, Wilson WH. Update on the pathogenesis, diagnosis, and therapy of AIDS-related lymphoma. Current Infectious Disease Reports 2003;5:176-184 [MEDLINE: 12642005]
78. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al.Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659 [MEDLINE: 12609827] (Pubitemid 36857717)
79. Martins RG, Finkelstein DM, Selden MV. The importance of beta, type II error, in negative trials in oncology. Proceeding of the American of Society of Clincial Oncology. 1997; Vol.15:415a.
80. Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR, et al.HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus. American Journal of Hematology 2003;72:216-219 [MEDLINE: 12605396] (Pubitemid 36258615)
81. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-2734 [MEDLINE: 11023505] (Pubitemid 30770367)
82. Miralles P, Rubio C, Berenguer J, Ribera JM, Calvo F, Mediavilla JD, et al.GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immune deficiency virus. Medicina Clínica (Barc) 2008;118:225-236 [MEDLINE: 11864547]
83. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, et al.Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. Journal of Acquired Immune Deficiency Syndromes 2007;44:167-173 [MEDLINE: 17117144] (Pubitemid 46292219)
84. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-1730 [MEDLINE: 9848347]
85. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. Journal of the American Medical Association 1994;272:122-124 [MEDLINE: 8015121] (Pubitemid 24206043)
86. Mounier N, Spina M, Gisselbrecht C.Modern management of non-Hodgkin lymphoma in HIV-infected patients. British Journal of Haematology 2007;136:685-698 [MEDLINE: 17229246] (Pubitemid 46246303)
87. Moylett EH, Shearer WT. HIV: clinical manifestations. The Journal of Allergy and Clinical Immunology 2002;110:3-16. [MEDLINE: 12110810]
88. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood 2006;107:13-20. [MEDLINE: 16099881]
89. Noy A. Update in HIV lymphoma. Current Opinion in Oncology 2006;18:449-455 [MEDLINE: 16894292]
90. Noy A. Update on HIV lymphoma. Current Oncology Reports 2007;9:384-390 [MEDLINE: 17706167]
91. N'Galy B, Bertozzi S, Ryder RW. Obstacles to the optimal management of HIV infection/AIDS in Africa. Journal of Acquired Immune Deficiency Syndromes 1990;3:430-437 [MEDLINE: 2313564] (Pubitemid 20154957)
92. Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ghannoum M, Dowlati A, et al.Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. Journal of The National Journal Institute 2002;94:718-732 [MEDLINE: 12011222] (Pubitemid 34567956)
93. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998;338:853-860 [MEDLINE: 9516219]
94. Palmieri C, Treibel T, Large O, Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. Quarterly Journal of Medicine 2006;99:811-826 [MEDLINE: 17085516] (Pubitemid 46024093)
95. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Seminars in Oncology 2006;18:469-478 [MEDLINE: 16894295] (Pubitemid 44199843)
96. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT, Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Annals of Internal Medicine 2008;20:728-736 [MEDLINE: 18490686]
97. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al.Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. Journal of Clincal Oncology 2009;27:884-890 [MEDLINE: 19114688]
98. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al.Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Journal Clinical Oncology 2001;19:2117-2118 [MEDLINE: 11304769] (Pubitemid 32366971)
99. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, et al.Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. Journal Clinical of Oncology 1993;11:1691-1702 [MEDLINE: 8355036] (Pubitemid 23277320)
100. Remick SC, Sedransk N, Haase RF, Blanchard CG, Ramnes CR, Nazeer T, et al.Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. American Journal of Hematology 2001;66:178-188 [MEDLINE: 11279624] (Pubitemid 32167455)
101. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
102. Scadden DT. AIDS-related malignancies. Annual Reviews of Medicine 2003;54:285-303. [MEDLINE: 12525676]
103. Schmidt-Wolf IG, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, et al.Treatment options of AIDS-related lymphoma. Expert Opinion on Pharmacotherapy 2003;4:1331-1343 [MEDLINE: 12877641]
104. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al.Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral Therapy 2007;12:931-939 [MEDLINE: 17926647] (Pubitemid 47492562)
105. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003;17:1787-1793 [MEDLINE: 12891064] (Pubitemid 37000096)
106. Sparano JA. Clinical aspects and management of AIDS-related lymphoma. European Journal of Cancer 2001;37:1296-1305. [MEDLINE: 11423261]
107. Sparano JA. Human immunodeficiency virus associated lymphoma. Current Opinion in Oncology 2003;15:372-378 [MEDLINE: 12960519]
108. Spina M, Tirelli U. Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Current Opinion in Oncology 2005;17:462-465 [MEDLINE: 16093796] (Pubitemid 41224927)
109. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, et al.Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. Journal of Clinical Oncology 2004;22:2177-2183 [MEDLINE: 15169806] (Pubitemid 41095153)
110. Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Treatment Review 2004;30:249-253 [MEDLINE: 15059648] (Pubitemid 38477270)
111. Stone A, Wheeler C, Barge A. Improving the design of phase II trials of cytostatic anticancer agents. Contemporary Clinical Trials 2007;28:138-145 [MEDLINE: 16843736] (Pubitemid 44937880)
112. Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clinical lymphoma 2003;4:86-92. [MEDLINE: 12960519] (Pubitemid 37304425)
113. Thomas JO. Acquired immunodeficiency syndrome-associated cancers in sub-Saharan Africa. Seminars in Oncology 2001;28:198-206. [MEDLINE: 11301383]
114. Joint United Nations Programme on HIV/ AIDS [UNAIDS], World Health Organization [WHO]. AIDS epidemic update: December 2000. Geneva, Switzerland, UNAIDS, 2000. 23, [5] p. (UNAIDS/00.44EWHO/CDS/CSR/EDC/2000.9). [: 164367 ]
115. Van Baarle D, Wolthers KC, Hovenkamp E, Niesters HG, Osterhaus AD, Miedema F, et al.Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. Journal of Infectious Diseases 2002;186:405-409 [MEDLINE: 12134237] (Pubitemid 34816324)
116. Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián G. Software to help manage the characteristics of included studies in Cochrane (www.cochrane.fcs.edu.ve/hrs). Venezuela: Universidad de Carabobo, 2006.
117. Zavala D, Martí-Carvajal A, Peña-Martí G, Comunián-Carrasco G. Software for data transformation for time-to-event outcomes [Available at www.cochrane.fcs.uc.edu.ve/deted]. Valencia: Universidad de Carabobo, 2007.